Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)
| 171.52 Delayed Data As of Sep 22 |  -2.30 / -1.32%Today’s Change | 169.85 Today|||52-Week Range 242.97 | -27.83% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | |||
| Revenue and Income | Net Revenues | 41.1M | 47.2M | 89.9M | 74.9M | |
| Cost of Goods Sold | -- | -- | -- | 1.8M | ||
| Depreciation And Amortization | 19.1M | 15.1M | 13.4M | 6.4M | ||
| Operating Expenses | Gross Income | -- | -- | -- | 66.7M | |
| General Expenses | 318.1M | 456.6M | 576.6M | 881.3M | ||
| Research And Development | 276.5M | 382.4M | 390.6M | 505.4M | ||
| Total Operating Expenses | 337.1M | 471.7M | 590.0M | 889.6M | ||
| Non-Operating Expenses | Operating Income | -296.0M | -424.6M | -500.1M | -814.7M | |
| Extraordinary Credit | 0.00 | 0.00 | 0.00 | 20.6M | ||
| Interest Expense On Debt | 0.00 | 1.2M | 800.0K | -- | ||
| Other Expenses | 76.0K | 7.4M | -2.2M | 4.2M | ||
| Income Taxes, Minority Interest and Extra Items | Pre-Tax Income | -290.1M | -410.1M | -490.9M | -760.7M | |
| Income Taxes | 0.00 | 0.00 | 0.00 | -823.0K | ||
| Net Income | -290.1M | -410.1M | -490.9M | -761.5M | ||
| Shares To Calculate EPS | Shares To Calculate EPS | 84.0M | 85.6M | 90.6M | 100.6M | |
| Shares To Calculate EPS Diluted | 84.0M | 85.6M | 90.6M | 100.6M | ||
| Earnings Per Share | EPS | -$3.45 | -$4.79 | -$5.42 | -$7.57 | |
| EPS Diluted | -$3.45 | -$4.79 | -$5.42 | -$7.57 | ||
